OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Personally I agree with both the views expressed by Fred 1 and Robstuff and both arguments are valid. Recently I decided to build up a stake in 175,000 OXB shares after reading that a leading broker has put a target price on the stock of 60p within the next 18 months.

Whether or not this is going to be achieved only time will tell. There are plenty of other safer investments on the stock market but I could not resist a punt on OXB because of the huge rewards if the share price moves upwards.

In 2004 I've held shares at different times in JKX, HTG, SEY and CPL although I made profits in all of these stocks I could have made a lot more money if I had held not sold them too early. I've got a hunch OXB will deliver and will hold onto them for as a long as it takes.

Merry Xmas to all and profitable New Year!

1704 - Seems we all agree all it takes now is for OXB to do their stuff and the market to respond. I am impressed that you classify a 175,000 holding as a punt !! Merry Christmas

have stocked up with oxb at knock down price and ready for the new yr tips to propell it forward, followed by more newsflow in the early part of next yr so look forward to nice gains from here.

For those of us who are patient on this one, here some good news:

Oxford Biomedica PLC
05 January 2005


FOR IMMEDIATE RELEASE 5 JANUARY 2005


OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT WITH BIOGEN IDEC

Oxford, UK: 5 January 2005 - Oxford BioMedica (LSE: OXB), the leading gene
therapy company, announced today that it has entered into an agreement to
license its LentiVector technology to Biogen Idec (NASDAQ: BIIB) for use in
research activities. Under the terms of the agreement, Oxford BioMedica will
receive an upfront licence payment and an annual maintenance fee. Further
financial details were not disclosed.

LentiVector, a lentivirus-based system, is one of the most powerful technologies
available for gene delivery to a wide range of cell and tissue types. The
technology has applications both in therapeutic products and drug discovery, as
a tool for target validation and the creation of targeted disease models. It
has also been shown to enhance the efficiency of developing transgenic birds and
mammals. Oxford BioMedica has a comprehensive portfolio of US and European
patents covering the LentiVector technology.

Oxford BioMedica's Senior Vice President Commercial Development, Peter Nolan,
said: 'We are delighted to add Biogen Idec to our list of licencees for the
LentiVector technology. This agreement is a further demonstration of the
technology's superiority and broad utility. We expect Oxford BioMedica's
LentiVector technology to become the system of choice for safe and effective
gene delivery in drug discovery and transgenics.'


For further information, please contact:

Oxford BioMedica plc: Tel: +44 (0)1865 783 000
Professor Alan Kingsman, Chief Executive

Peter Nolan, SVP Commercial Development

City/Financial Enquiries: Tel: +44 (0)20 7466 5000
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications

Scientific/Trade Press Enquiries: Tel: +44 (0)20 7886 8150
Sue Charles/ Katja Stout/ Ashley Lilly

Northbank Communications


Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

In addition to its technical expertise in gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing know-how. The development
pipeline includes two novel anti-cancer products in clinical trials; two
neurotherapy products in advanced preclinical development for Parkinson's
disease and retinopathy; and three further preclinical neurotherapy products.
The Company is underpinned by an extensive preclinical and research portfolio
and over 80 patent families, which represents one of the broadest patent estates
in the field.

The Company has established a neurotherapy pipeline of product candidates based
on its LentiVector technology, which includes ProSavin(R) for Parkinson's
disease, RetinoStat(R) for retinopathy, MoNuDin(R) for motor neuron disease,
SMN1-G for spinal muscular atrophy and Innurex(R) for nerve repair. Current
licencees of the LentiVector technology for drug discovery and transgenic
applications include Merck & Co and Viragen.


Further information is available at
http://www.oxfordbiomedica.co.uk



2. LentiVector technology

Oxford BioMedica's LentiVector gene delivery technology, based on lentiviral
vectors, is arguably the most potent system currently available for treating a
range of diseases, particularly those of the central nervous system. Oxford
BioMedica has shown that its lentiviral vectors are able to deliver genes with
high efficiency to a variety of both dividing and non-dividing cells, including
neurons in the brain.

Oxford BioMedica has three issued US patents and a European patent for its
LentiVector technology. These include broad composition of matter claims and
methods of production claims for lentiviral vector gene delivery systems of both
human and non-human origin. The patents also cover derivatives of lentiviral
vector systems that, unlike many versions of lentiviral vectors, have real
clinical utility because of their safety. The Oxford BioMedica team was the
first to construct lentiviral vectors that contain no viral genes at all, and
which comprise the minimum number of viral components in the viral particles. It
is this minimisation of the vectors that is the subject of these patents. This
work was done using vectors based on HIV and Equine Infectious Anaemia Virus
(EIAV), a horse virus that is not linked to any disease in humans.


3. Biogen Idec

Biogen Idec creates new standards of care in oncology and immunology. As a
global leader in the development, manufacturing, and commercialization of novel
therapies, Biogen Idec transforms scientific discoveries into advances in human
healthcare. For product labeling, press releases and additional information
about the company, please visit
http://www.biogenidec.com/




This information is provided by RNS
The company news service from the London Stock Exchange

Another licence agreement, more good news just the start to what should be a massive yr for oxb.

We do seem to have a persistent seller,25k 10k though the trades list doe's not reflect the true amount of buying, some of the other sells are infact buys.

rvitler, you're right. More good news but, as always, the SP does absolutely f**k all. What on earth does this one need to start it heading skywards?

And now its below where it was before the announcement on the 5th! Heaven help us if they ever get any bad news....or perhaps the SP will actually go up!

About to explode?....

or implode?....

we need some good positive trial results on this one.

positive news so it can go down you mean. COME ON!!! you b***ard thing get moving up

Love the comment AMharry4899 - I think you captured all our thoughts! Agree, so frustrating when if in the US, this co's sp would be 20 times the price.

Aaah...20x...that would pay for tonight's bottle of wine...

Someone has just acquired 3% OF THE CO and the shares still go down. If I sold some the sp would shoot up, so lets just say i've sold today.

OXB is really not getting places - it has been in this region of 16-19p for ages.

OXB shall be a success story of 2005-6, with licence agreements underpinning the development budget. I keep buying around 17p. I hold 120,000 stock. management are really excellent, with the best contacts in the business. They are almost above th3e biz .. like British Bio should have been , but got tainted . Prof Kingsman didn't let himself be so influenced.
You should see 30p tested by summer .If not later in the year, thanks to Trovax and other developments. if you are intersteed in increasing a sum of cash from X to X plus 50% in one year, this is such a company. If you want to do it ina fortnight, try the pools.

It's time to get back in - with the sellers out the way, and price hitting 17 again, good news to come will push this overlooked Gem up above 20 and the graph will show a golden cross meaning onwards and upwards this yr to 45p

3 companies have acquired a sizeable stake, who are the Sputnik Group? Let's hope they don't get taken over as I want these long term as they're going to be worth many pounds. Something's afoot anyway, Trovax is coming of age and will be a rael money spinner, the other technologies are so awesome, they're just too difficult to understand but the applications are endless and worth a fortune, no reason for this low price.

Another licence deal would kick start it or news of the trials, there's a lot of newsflow tocome, progress reports and possible big deals so price could take off.

Some very good buys - 500k etc so why the sudden interest?